[CAS NO. 1359968-33-4] Ganciclovir hydrate

Ships within

Stock

Price

Qty

Total

COA

Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.

Catalog:	HY-13637B
Brand:	MCE
CAS:	1359968-33-4

Overview

MDL	-
Molecular Weight	273.25
Molecular Formula	C9H15N5O5
SMILES	O=C1N=C(NC2=C1N=CN2COC(CO)CO)N.O

For research use only. We do not sell to patients.

11 Publications Citing Use of MCE

[1]Cell. 2020 Nov 25;183(5):1402-1419.e18.
[2]Brain Behav Immun. 2019 Aug;80:394-405.
[3]Sci Data. 2022 Oct 8;9(1):610.
[4]J Nanobiotechnology. 2022 Jul 20;20(1):340.
[5]Biochem Pharmacol. 2022 Jan 15;114917.
[6]J Virol. 2017 Jan 18;91(3). pii: e02152-16.
[7]Cells. 2019 Dec 20;9(1):31.
[8]Antiviral Res. 2021 Jun 28;105124.
[9]Eur J Pharm Sci. 2019 Jan 15;127:29-37.
[10]Microchem J. 2021, 106587.
[11]Pharmacol Res Perspect. 2020 Apr;8(2):e00575.

Summary

Ganciclovir (BW 759) hydrate, a nucleoside analogue, is an orally active antiviral agent with activity against CMV . Ganciclovir hydrate also has activity in vitro against members of the herpes group and some other DNA viruses. Ganciclovir hydrate inhibits the in vitro replication of human herpes viruses (HSV 1 and 2, CMV) and adenovirus serotypes 1, 2, 4, 6, 8, 10, 19, 22 and 28. Ganciclovir hydrate has an IC ₅₀ of 5.2 μM for feline herpesvirus type-1 ( FHV-1 ) and can diffuse into the brain ^[1] ^[2] ^[3] .

IC50 & Target

CMV

HSV-1

HSV-2

FHV-1

5.2 μM (IC ₅₀ )

In Vitro

Ganciclovir (BW 759) is an acyclic deoxyguanosine analog structurally similar to acyclovir but with superior activity against CMV. The median Ganciclovir concentration required to inhibit viral replication by 50 percent is 2.15 μM versus 72 μM for acyclovir ^[4] .
The primary mechanism of Ganciclovir action against CMV is inhibition of the replication of viral DNA by ganciclovir-5'-triphosphate (ganciclovir-TP). This inhibition includes a selective and potent inhibition of the viral DNA polymerase. Ganciclovir is metabolized to the triphosphate form by primarily three cellular enzymes: a deoxyguanosine kinase induced by CMV-infected cells; guanylate kinase; and phosphoglycerate kinase ^[5] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Ganciclovir (BW 759) (50 mg/kg; i.p.; twice a day for five injections) significantly decreases white blood cells, red blood cells and platelets in newborn mice, and can diffuse into the brain and the perilymphatic space of the inner ear ^[3] .
Ganciclovir (1-80 mg/kg; i.h.; daily for 5 days) delays murine cytomegalovirus (MCMV)-induced wasting syndrome and mortality ^[6] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Non-inbred Oncins France 1 (OF1) mice and albino rats non-immunized for MCMV ^[3]
Dosage:	50 mg/kg
Administration:	Intraperitoneal injection, twice a day for five injections (mice) or 3 days (adult rats) (Pharmacokinetic Study)
Result:	In adult rats, the intracochlear diffusion of Ganciclovir was shown to achieve the same concentration as in blood. In gestating mice, transplacental diffusion was observed, with a fetal-to-maternal blood ratio of 0.5. In newborn mice, the plasma concentration profile of Ganciclovir showed a peak at 2 h followed by a gradual decrease. In adult mice, the concentration peaked at 1 h, but became undetectable by 2 h after injection. Significantly decreased white blood cells, red blood cells and platelets in newborn mice.

Animal Model:	Female SCID mice inoculated with MCMV ^[6]
Dosage:	0, 1, 10, 80 and 160 mg/kg
Administration:	Subcutaneous injection, once daily for 5 days
Result:	Dose dependently delayed the wasting syndrome and mortality in a dose range up to 80 mg/kg per day, whereas a dose of 160 mg/kg per day induced reversible side-effects.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT00001062	National Institute of Allergy and Infectious Diseases (NIAID)	Cytomegalovirus Retinitis\|HIV Infections		Phase 1
NCT00000143	Johns Hopkins Bloomberg School of Public Health	Cytomegalovirus Retinitis\|HIV Infections	May 1997	Phase 3
NCT03217474	Chunxiao Wang\|Sun Yat-sen University	Herpes Simplex Keratitis	July 20, 2017	Not Applicable
NCT00005025	John Stoddard Cancer Center at Iowa Methodist Medical Center\|National Cancer Institute (NCI)	Fallopian Tube Cancer\|Ovarian Cancer\|Primary Peritoneal Cavity Cancer	June 2000	Phase 2
NCT00000995	National Institute of Allergy and Infectious Diseases (NIAID)	Cytomegalovirus Infections\|HIV Infections		Not Applicable
NCT00001061	National Institute of Allergy and Infectious Diseases (NIAID)\|Facet Biotech	Cytomegalovirus Retinitis\|HIV Infections		Phase 2
NCT00002015	Roche Global Development\|NIH AIDS Clinical Trials Information Service	Cytomegalovirus Retinitis\|HIV Infections		Not Applicable
NCT00241345	Washington University School of Medicine	Cytomegalovirus Infections	June 2004	Phase 3
NCT00000989	National Institute of Allergy and Infectious Diseases (NIAID)\|Schering-Plough\|Hoffmann-La Roche	Cytomegalovirus Retinitis\|HIV Infections		Not Applicable
NCT00002251	Hoffmann-La Roche\|NIH AIDS Clinical Trials Information Service	Cytomegalovirus Infections\|HIV Infections		Not Applicable
NCT00093704	Jonsson Comprehensive Cancer Center	Lymphoma\|Lymphoproliferative Disorder	March 2005	Phase 1
NCT00006264	AIDS Malignancy Consortium\|National Cancer Institute (NCI)	Lymphoma	July 2000	Phase 2
NCT00004573	National Center for Research Resources (NCRR)	Cytomegalovirus Infections		Not Applicable
NCT00000856	National Institute of Allergy and Infectious Diseases (NIAID)	Encephalopathy\|HIV Infections\|Radiculitis		Phase 1
NCT00016068	Fred Hutchinson Cancer Center\|National Cancer Institute (NCI)	Infection	January 2001	Phase 3
NCT00530218	City of Hope Medical Center\|National Cancer Institute (NCI)	Myelodysplastic+Myeloproliferative Neoplasm, Unclassifiable\|Leukemia\|Lymphoma\|Multiple Myeloma\|MDS\|Myelodysplastic+Myeloproliferative Diseases	March 1999	Phase 2
NCT00141037	National Institute of Allergy and Infectious Diseases (NIAID)\|Astellas Pharma Inc\|Hoffmann-La Roche	Kidney Diseases\|Kidney Transplantation\|Kidney Transplant\|Renal Transplantation\|Renal Transplant	March 2004	Phase 1\|Phase 2
NCT00716911	City of Hope Medical Center\|National Cancer Institute (NCI)\|National Institute of Allergy and Infectious Diseases (NIAID)	Chronic Myeloproliferative Disorders\|Leukemia\|Lymphoma\|Multiple Myeloma and Plasma Cell Neoplasm\|Myelodysplastic Syndromes\|Myelodysplastic+Myeloproliferative Neoplasms\|Nonneoplastic Condition	January 2000	Not Applicable
NCT00002273	Hoffmann-La Roche\|NIH AIDS Clinical Trials Information Service	Colitis\|HIV Infections		Not Applicable
NCT02973464	First Affiliated Hospital Xi´an Jiaotong University	Renal Transplant Recipients	June 2016
NCT01335932	Fred Hutchinson Cancer Center\|National Heart, Lung, and Blood Institute (NHLBI)\|Genentech, Inc.	Acute Lung Injury\|Acute Respiratory Distress Syndrome\|Respiratory Failure	March 10, 2011	Phase 2
NCT00000698	National Institute of Allergy and Infectious Diseases (NIAID)	Cytomegalovirus Retinitis\|HIV Infections		Phase 3
NCT01600365	Adapt Produtos Oftalmológicos Ltda.	Conjunctivitis\|Adenovirus.	May 2012	Phase 3
NCT01349452	Federal University of São Paulo	Conjunctivitis, Viral\|Adenoviridae Infections	August 2009	Not Applicable
NCT01647529	Singapore National Eye Centre	Cytomegalovirus Anterior Segment Infection\|Anterior Uveitis\|Endotheliitis	July 2012	Not Applicable
NCT00000766	National Institute of Allergy and Infectious Diseases (NIAID)	Cytomegalovirus Retinitis\|HIV Infections		Phase 2
NCT00005057	National Human Genome Research Institute (NHGRI)\|National Cancer Institute (NCI)	Melanoma (Skin)	March 2000	Phase 1
NCT00000688	National Institute of Allergy and Infectious Diseases (NIAID)\|Hoffmann-La Roche	Cytomegalovirus Retinitis\|HIV Infections		Phase 3
NCT00000768	National Institute of Allergy and Infectious Diseases (NIAID)\|Hoffmann-La Roche	Colitis\|HIV Infections		Phase 1
NCT03586284	University of California, San Francisco\|Huang Pacific Foundation\|Khon Kaen University\|King Chulalongkorn Memorial Hospital	Cytomegalovirus Anterior Uveitis	March 15, 2020	Phase 2\|Phase 3
NCT01199562	City of Hope Medical Center\|National Cancer Institute (NCI)	Hematopoietic+Lymphoid Cancer\|Accelerated Phase Chronic Myelogenous Leukemia\|Acute Undifferentiated Leukemia\|Adult Acute Lymphoblastic Leukemia in Remission\|Adult Acute Myeloid Leukemia in Remission\|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities\|Adult Acute Myeloid Leukemia With Del(5q)\|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)\|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)\|Adult Grade III Lymphomatoid Granulomatosis\|Adult Nasal Type Extranodal NK+T-cell Lymphoma\|Anaplastic Large Cell Lymphoma\|Angioimmunoblastic T-cell Lymphoma\|Aplastic Anemia\|Atypical Chronic Myeloid Leukemia, BCR-ABL Negative\|Blastic Phase Chronic Myelogenous Leukemia\|Chronic Eosinophilic Leukemia\|Chronic Myelomonocytic Leukemia\|Chronic Neutrophilic Leukemia\|Chronic Phase Chronic Myelogenous Leukemia\|Contiguous Stage II Adult Burkitt Lymphoma\|Contiguous Stage II Adult Diffuse Large Cell Lymphoma\|Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma\|Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma\|Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma\|Contiguous Stage II Adult Lymphoblastic Lymphoma\|Contiguous Stage II Grade 1 Follicular Lymphoma\|Contiguous Stage II Grade 2 Follicular Lymphoma\|Contiguous Stage II Grade 3 Follicular Lymphoma\|Contiguous Stage II Mantle Cell Lymphoma\|Contiguous Stage II Marginal Zone Lymphoma\|Contiguous Stage II Small Lymphocytic Lymphoma\|Cutaneous B-cell Non-Hodgkin Lymphoma\|Cytomegalovirus Infection\|de Novo Myelodysplastic Syndromes\|Essential Thrombocythemia\|Extramedullary Plasmacytoma\|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue\|Intraocular Lymphoma\|Isolated Plasmacytoma of Bone\|Mast Cell Leukemia\|Meningeal Chronic Myelogenous Leukemia\|Myelodysplastic+Myeloproliferative Neoplasm, Unclassifiable\|Nodal Marginal Zone B-cell Lymphoma\|Noncontiguous Stage II Adult Burkitt Lymphoma\|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma\|Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma\|Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma\|Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma\|Noncontiguous Stage II Adult Lymphoblastic Lymphoma\|Noncontiguous Stage II Grade 1 Follicular Lymphoma\|Noncontiguous Stage II Grade 2 Follicular Lymphoma\|Noncontiguous Stage II Grade 3 Follicular Lymphoma\|Noncontiguous Stage II Mantle Cell Lymphoma\|Noncontiguous Stage II Marginal Zone Lymphoma\|Noncontiguous Stage II Small Lymphocytic Lymphoma\|Polycythemia Vera\|Post-transplant Lymphoproliferative Disorder\|Previously Treated Myelodysplastic Syndromes\|Primary Myelofibrosis\|Primary Systemic Amyloidosis\|Progressive Hairy Cell Leukemia, Initial Treatment\|Prolymphocytic Leukemia\|Recurrent Adult Acute Lymphoblastic Leukemia\|Recurrent Adult Acute Myeloid Leukemia\|Recurrent Adult Burkitt Lymphoma\|Recurrent Adult Diffuse Large Cell Lymphoma\|Recurrent Adult Diffuse Mixed Cell Lymphoma\|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma\|Recurrent Adult Grade III Lymphomatoid Granulomatosis\|Recurrent Adult Hodgkin Lymphoma\|Recurrent Adult Immunoblastic Large Cell Lymphoma\|Recurrent Adult Lymphoblastic Lymphoma\|Recurrent Adult T-cell Leukemia+Lymphoma\|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma\|Recurrent Grade 1 Follicular Lymphoma\|Recurrent Grade 2 Follicular Lymphoma\|Recurrent Grade 3 Follicular Lymphoma\|Recurrent Mantle Cell Lymphoma\|Recurrent Marginal Zone Lymphoma\|Recurrent Mycosis Fungoides+Sezary Syndrome\|Recurrent Small Lymphocytic Lymphoma\|Refractory Chronic Lymphocytic Leukemia\|Refractory Hairy Cell Leukemia\|Refractory Multiple Myeloma\|Relapsing Chronic Myelogenous Leukemia\|Secondary Acute Myeloid Leukemia\|Secondary Myelodysplastic Syndromes\|Secondary Myelofibrosis\|Splenic Marginal Zone Lymphoma\|Stage 0 Chronic Lymphocytic Leukemia\|Stage I Adult Burkitt Lymphoma\|Stage I Adult Diffuse Large Cell Lymphoma\|Stage I Adult Diffuse Mixed Cell Lymphoma\|Stage I Adult Diffuse Small Cleaved Cell Lymphoma\|Stage I Adult Hodgkin Lymphoma\|Stage I Adult Immunoblastic Large Cell Lymphoma\|Stage I Adult Lymphoblastic Lymphoma\|Stage I Adult T-cell Leukemia+Lymphoma\|Stage I Chronic Lymphocytic Leukemia\|Stage I Cutaneous T-cell Non-Hodgkin Lymphoma\|Stage I Grade 1 Follicular Lymphoma\|Stage I Grade 2 Follicular Lymphoma\|Stage I Grade 3 Follicular Lymphoma\|Stage I Mantle Cell Lymphoma\|Stage I Marginal Zone Lymphoma\|Stage I Multiple Myeloma\|Stage I Mycosis Fungoides+Sezary Syndrome\|Stage I Small Lymphocytic Lymphoma\|Stage II Adult Hodgkin Lymphoma\|Stage II Adult T-cell Leukemia+Lymphoma\|Stage II Chronic Lymphocytic Leukemia\|Stage II Cutaneous T-cell Non-Hodgkin Lymphoma\|Stage II Multiple Myeloma\|Stage II Mycosis Fungoides+Sezary Syndrome\|Stage III Adult Burkitt Lymphoma\|Stage III Adult Diffuse Large Cell Lymphoma\|Stage III Adult Diffuse Mixed Cell Lymphoma\|Stage III Adult Diffuse Small Cleaved Cell Lymphoma\|Stage III Adult Hodgkin Lymphoma\|Stage III Adult Immunoblastic Large Cell Lymphoma\|Stage III Adult Lymphoblastic Lymphoma\|Stage III Adult T-cell Leukemia+Lymphoma\|Stage III Chronic Lymphocytic Leukemia\|Stage III Cutaneous T-cell Non-Hodgkin Lymphoma\|Stage III Grade 1 Follicular Lymphoma\|Stage III Grade 2 Follicular Lymphoma\|Stage III Grade 3 Follicular Lymphoma\|Stage III Mantle Cell Lymphoma\|Stage III Marginal Zone Lymphoma\|Stage III Multiple Myeloma\|Stage III Mycosis Fungoides+Sezary Syndrome\|Stage III Small Lymphocytic Lymphoma\|Stage IV Adult Burkitt Lymphoma\|Stage IV Adult Diffuse Large Cell Lymphoma\|Stage IV Adult Diffuse Mixed Cell Lymphoma\|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma\|Stage IV Adult Hodgkin Lymphoma\|Stage IV Adult Immunoblastic Large Cell Lymphoma\|Stage IV Adult Lymphoblastic Lymphoma\|Stage IV Adult T-cell Leukemia+Lymphoma\|Stage IV Chronic Lymphocytic Leukemia\|Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma\|Stage IV Grade 1 Follicular Lymphoma\|Stage IV Grade 2 Follicular Lymphoma\|Stage IV Grade 3 Follicular Lymphoma\|Stage IV Mantle Cell Lymphoma\|Stage IV Marginal Zone Lymphoma\|Stage IV Mycosis Fungoides+Sezary Syndrome\|Stage IV Small Lymphocytic Lymphoma\|T-cell Large Granular Lymphocyte Leukemia\|Waldenstrom Macroglobulinemia	December 2010
NCT00002096	Hoffmann-La Roche\|NIH AIDS Clinical Trials Information Service	Cytomegalovirus Infections\|HIV Infections		Phase 1
NCT00006340	Boston Medical Center	Leukemia\|Lymphoma\|Precancerous Condition\|Small Intestine Cancer	December 1994	Phase 1
NCT00006216	Louisiana State University Health Sciences Center in New Orleans\|National Cancer Institute (NCI)	Malignant Mesothelioma	August 1997	Phase 1
NCT00002156	Ionis Pharmaceuticals, Inc.\|NIH AIDS Clinical Trials Information Service	Cytomegalovirus Retinitis\|HIV Infections		Phase 2
NCT00000894	National Institute of Allergy and Infectious Diseases (NIAID)	Cytomegalovirus Retinitis\|HIV Infections		Phase 4
NCT00917826	HemaQuest Pharmaceuticals Inc.\|Boston University	EBV Lymphomas\|Lympho-proliferative Diseases	September 2008	Phase 2
NCT00002034	Hoffmann-La Roche\|NIH AIDS Clinical Trials Information Service	Cytomegalovirus Retinitis\|HIV Infections		Not Applicable
NCT01185223	Pierrel Research Europe GmbH\|Roche Pharma AG	Allogeneic Stem Cell Transplantation	September 2010	Phase 3
NCT00002257	Hoffmann-La Roche\|NIH AIDS Clinical Trials Information Service	Cytomegalovirus Retinitis\|HIV Infections		Not Applicable
NCT00014911	National Institute of Allergy and Infectious Diseases (NIAID)\|Immune Tolerance Network (ITN)	Diabetes Mellitus, Insulin-Dependent	April 2001	Phase 2
NCT00264368	University of Oslo School of Pharmacy	Acute Renal Failure\|Cytomegalovirus Infections\|Multi Organ Failure	December 2005	Phase 4
NCT00002095	Hoffmann-La Roche\|NIH AIDS Clinical Trials Information Service	Cytomegalovirus Infections\|HIV Infections		Not Applicable
NCT02202564	Huazhong University of Science and Technology\|Beijing YouAn Hospital	Liver Cancer\|Hepatocellular Carcinoma	October 2006	Phase 2
NCT00373165	Lower Saxony Center for Nephrology	DNA Virus Infection\|Herpesviridae Infections\|Cytomegalovirus Infection	August 2000	Phase 4
NCT00000665	National Institute of Allergy and Infectious Diseases (NIAID)\|Johns Hopkins University	Cytomegalovirus Retinitis\|HIV Infections		Not Applicable
NCT00001034	National Institute of Allergy and Infectious Diseases (NIAID)\|Hoffmann-La Roche	Cytomegalovirus Retinitis\|HIV Infections\|Gastrointestinal Diseases		Phase 2
NCT00002024	Hoffmann-La Roche\|NIH AIDS Clinical Trials Information Service	Cytomegalovirus Infections\|HIV Infections		Not Applicable
NCT00964756	University of Alabama at Birmingham\|National Cancer Institute (NCI)	Ovarian Cancer	August 2009	Phase 1
NCT00000134	Johns Hopkins Bloomberg School of Public Health\|National Eye Institute (NEI)\|National Institute of Allergy and Infectious Diseases (NIAID)\|Johns Hopkins University\|University of Wisconsin, Madison\|Baylor College of Medicine\|Tulane University School of Medicine\|Icahn School of Medicine at Mount Sinai\|New York Presbyterian Hospital\|New York University\|Northwestern University\|University of California, Los Angeles\|University of California, San Francisco\|University of California, San Diego\|University of Miami\|University of North Carolina, Chapel Hill\|Memorial Sloan Kettering Cancer Center	HIV Infections\|Acquired Immunodeficiency Syndrome\|Cytomegalovirus Retinitis	December 1992	Phase 3
NCT00002824	Abramson Cancer Center of the University of Pennsylvania\|National Cancer Institute (NCI)	Brain and Central Nervous System Tumors	February 1996	Phase 1
NCT00000136	Johns Hopkins Bloomberg School of Public Health\|National Eye Institute (NEI)\|Johns Hopkins University\|University of Wisconsin, Madison\|Baylor College of Medicine\|Louisiana State University Health Sciences Center in New Orleans\|New York Presbyterian Hospital\|Icahn School of Medicine at Mount Sinai\|NYU Langone Health\|Northwestern University\|University of California, Los Angeles\|University of California, San Diego\|University of California, San Francisco\|University of Miami\|University of Massachusetts, Worcester\|Memorial Sloan Kettering Cancer Center	HIV Infections\|Cytomegalovirus Retinitis	March 1990	Phase 3
NCT00006480	Fred Hutchinson Cancer Center\|National Cancer Institute (NCI)	Neuroblastoma	May 2000	Phase 1
NCT00431353	Hoffmann-La Roche	Cytomegalovirus Infections	April 2004	Phase 4
NCT00002135	Hoffmann-La Roche\|NIH AIDS Clinical Trials Information Service	Cytomegalovirus Retinitis\|HIV Infections		Not Applicable
NCT00001100	National Institute of Allergy and Infectious Diseases (NIAID)	Cytomegalovirus Infections		Phase 3
NCT00002070	Schering-Plough\|NIH AIDS Clinical Trials Information Service	Cytomegalovirus Retinitis\|HIV Infections		Phase 3
NCT00002330	Roche Global Development\|NIH AIDS Clinical Trials Information Service	Cytomegalovirus Retinitis\|HIV Infections		Not Applicable
NCT02943057	Singapore National Eye Centre	Cytomegalovirus Infections	October 2016	Phase 4
NCT00000805	National Institute of Allergy and Infectious Diseases (NIAID)	Cytomegalovirus Infections\|HIV Infections		Phase 1
NCT00372229	Hoffmann-La Roche	Cytomegalovirus Infections	May 2006	Phase 3
NCT00002247	Hoffmann-La Roche\|NIH AIDS Clinical Trials Information Service	Cytomegalovirus Retinitis\|HIV Infections		Not Applicable
NCT00002377	Hoffmann-La Roche	Cytomegalovirus Retinitis\|HIV Infections	January 1997	Phase 3
NCT00986557	University Hospital Birmingham\|National Cancer Institute (NCI)	Graft Versus Host Disease\|Nonneoplastic Condition	September 2009	Phase 2
NCT03698435	University Medical Center Groningen	Cytomegalovirus Infections	May 25, 2018
NCT04706507	Fred Hutchinson Cancer Center\|National Heart, Lung, and Blood Institute (NHLBI)	Acute Respiratory Failure	June 29, 2021	Phase 3
NCT02931539	Shire\|Takeda	Cytomegalovirus (CMV)	December 22, 2016	Phase 3
NCT03598452	Aier School of Ophthalmology, Central South University	Infection Viral\|Uveitis, Posterior	January 2014	Not Applicable
NCT02152358	Assistance Publique Hopitaux De Marseille	Viral Pneumonia	March 2014	Phase 4
NCT04132115	Azienda Sanitaria-Universitaria Integrata di Udine	Therapeutic Drug Monitoring\|Subarachnoid Hemorrhage\|Intracerebral Hemorrhage	October 1, 2019
NCT00031434	National Institute of Allergy and Infectious Diseases (NIAID)	Cytomegalovirus Infections	July 2002	Phase 1\|Phase 2
NCT00000970	National Institute of Allergy and Infectious Diseases (NIAID)\|Astra USA\|Hoffmann-La Roche	Cytomegalovirus Retinitis\|HIV Infections		Phase 1
NCT00002299	Hoffmann-La Roche\|NIH AIDS Clinical Trials Information Service	Cytomegalovirus Retinitis\|HIV Infections		Not Applicable
NCT03699254	Maimónides Biomedical Research Institute of Córdoba\|Instituto de Salud Carlos III	Transplantation Infection\|Cytomegalovirus Infections	April 5, 2019	Phase 3
NCT00023231	National Institute of Allergy and Infectious Diseases (NIAID)	End-Stage Renal Disease	February 2001	Not Applicable
NCT00000673	National Institute of Allergy and Infectious Diseases (NIAID)	Cytomegalovirus Retinitis\|HIV Infections		Phase 1
NCT00002134	Roche Global Development\|NIH AIDS Clinical Trials Information Service	Cytomegalovirus Retinitis\|HIV Infections		Not Applicable
NCT00001999	American National Red Cross\|NIH AIDS Clinical Trials Information Service	Cytomegalovirus Retinitis\|HIV Infections		Not Applicable
NCT00217503	National Cancer Institute (NCI)	Lymphoma	July 2005	Phase 2
NCT00000668	National Institute of Allergy and Infectious Diseases (NIAID)\|Hoffmann-La Roche	Cytomegalovirus Retinitis\|HIV Infections		Phase 1
NCT00497796	Shire\|Takeda	Cytomegalovirus Infections	July 23, 2007	Phase 3
NCT00002025	Hoffmann-La Roche\|NIH AIDS Clinical Trials Information Service	Cytomegalovirus Infections\|Cytomegalovirus Retinitis\|HIV Infections		Not Applicable
NCT03004261	Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine\|Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China	Cytomegalovirus Infections\|Hematological Disease	November 2016	Phase 4
NCT04225780	Peking University People´s Hospital	Cytomegalovirus Infections	February 1, 2020	Phase 1\|Phase 2
NCT00947141	University College, London	Viraemia	February 2003	Phase 4
NCT00004278	National Center for Research Resources (NCRR)\|National Institute of Allergy and Infectious Diseases (NIAID)\|Office of Rare Diseases (ORD)	Cytomegalovirus Infections	December 1991	Phase 3
NCT04478474	New York Medical College\|Merck Sharp & Dohme LLC	Cytomegalovirus Infections	September 15, 2020

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

References

[1] Faulds D, et al. Ganciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegalovirus infections. Drugs. 1990;39(4):597-638.
[2] Maggs DJ, et al. In vitro efficacy of ganciclovir, cidofovir, penciclovir, foscarnet, idoxuridine, and acyclovir against feline herpesvirus type-1. Am J Vet Res. 2004 Apr;65(4):399-403.
[3] Boujemla I, et al. Pharmacokinetics and tissue diffusion of ganciclovir in mice and rats. Antiviral Res. 2016;132:111-115.
[4] Fletcher CV, et al. Evaluation of ganciclovir for cytomegalovirus disease. DICP. 1989 Jan;23(1):5-12.
[5] Matthews T, et al. Antiviral activity and mechanism of action of ganciclovir. Rev Infect Dis. 1988 Jul-Aug;10 Suppl 3:S490-4.
[6] Duan J, Paris W, Kibler P, Bousquet C, Liuzzi M, Cordingley MG. Dose and duration-dependence of ganciclovir treatment against murine cytomegalovirus infection in severe combined immunodeficient mice. Antiviral Res. 1998;39(3):189-197.

Request a Quote

Please fill in your details below to request a COA for our product. We will send the COA to the provided email address promptly.

Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.

Information

Shipping
Privacy notice
Terms of Service
About us
Contact us

Customer service

Search
Custom Synthesis

My account

My account
Orders
Addresses
Shopping cart